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Multiple sclerosis (MS) is a complex trait in which alleles at or near the class II loci HLA-DRB1 and HLA-DQB1 contribute
significantly to genetic risk. HLA-DRB1*15 and HLA-DRB1*17-bearing haplotypes and interactions at the HLA-DRB1
locus increase risk of MS but it has taken large samples to identify resistance HLA-DRB1 alleles. In this investigation of
7,093 individuals from 1,432 MS families, we have assessed the validity, mode of inheritance, associated genotypes,
and the interactions of HLA-DRB1 resistance alleles. HLA-DRB1*14-, HLA-DRB1*11-, HLA-DRB1*01-, and HLA-DRB1*10-
bearing haplotypes are protective overall but they appear to operate by different mechanisms. The first type of
resistance allele is characterised by HLA-DRB1*14 and HLA-DRB1*11. Each shows a multiplicative mode of inheritance
indicating a broadly acting suppression of risk, but a different degree of protection. In contrast, a second type is
exemplified by HLA-DRB1*10 and HLA-DRB1*01. These alleles are significantly protective when they interact
specifically in trans with HLA-DRB1*15-bearing haplotypes. HLA-DRB1*01 and HLA-DRB1*10 do not interact with HLA-
DRB1*17, implying that several mechanisms may be operative in major histocompatibility complex–associated MS
susceptibility, perhaps analogous to the resistance alleles. There are major practical implications for risk and for the
exploration of mechanisms in animal models. Restriction of antigen presentation by HLA-DRB1*15 seems an
improbably simple mechanism of major histocompatibility complex–associated susceptibility.
Citation: Ramagopalan SV, Morris AP, Dyment DA, Herrera BM, DeLuca GC, et al. (2007) The inheritance of resistance alleles in multiple sclerosis. PLoS Genet 3(9): e150. doi:10.
1371/journal.pgen.0030150
Introduction
Multiple sclerosis (MS) is a complex neurological disease
with a strong genetic predisposition, as demonstrated by
genetic–epidemiological studies [1–3]. However, the mapping
of putative susceptibility genes has proven difﬁcult. The
imputation of many non–major histocompatibility complex
(MHC) genes by analogies with experimental models and the
drop in concordance between monozygotic and dizygotic
twins, has not been validated by genome scans. In genome-
wide studies with enough power to detect relatively small
effects, the MHC has consistently been the only locus linked
to MS [4]. This indicates that the MHC is the key susceptibility
locus in MS and other susceptibility genes contribute
relatively little to overall risk [31].
Accordingly, polymorphisms at the major histocompatibil-
ity locus (MHC) have undergone renewed study. Genes in the
HLA class I region were originally shown to be associated
with MS [5,6] but stronger associations were subsequently
observed in the class II region of the MHC [7]. This class II
association has been ﬁne mapped to the extended haplotype
HLA-DQA1*0102-DQB1*0602-DRB1*1501-DRB5*0101 [8,9].
The human leukocyte antigen (HLA) association in a large
Canadian MS population was recently revisited [10] and the
situation was found to be much more complex than originally
conceived. The study of interactions was only productive
when a large sample was analysed (n¼4,347 individuals). The
HLA-DRB1*17 allele has long been known to be associated
with susceptibility in other groups, in particular the
Sardinian and the Swedish MS populations [11,12] and this
was conﬁrmed in the Canadian population.
There were clear indications of resistance alleles, in
particular, HLA-DRB1*14, and the same approach was
recently repeated in a study of American and European
families [13] with similar results. Additionally, HLA-DRB1*08
and DRB1*01 showed effects on MS risk in the presence of
HLA-DRB1*15 [10]. We present here an investigation of an
expanded series of Canadian MS families aimed at elucidating
the inheritance pattern of MS susceptibility and resistance
alleles.
Results
A total of 7,093 individuals from 1,432 families have been
typed as part of the Canadian Collaborative Project on the
Genetic Susceptibility to MS (CCPGSMS). This includes 2,454
individuals with deﬁnite MS and 4,639 of their unaffected
ﬁrst-degree relatives.
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In the total sample, HLA-DRB1*15 was transmitted 953
times and not transmitted 392 times; v
2 ¼ 233.99 (p ¼ 8.0 3
10
 53). To avoid confounding results due to the over trans-
mission of HLA-DRB1*15, transmissions from only non-HLA-
DRB1*15-bearing parents were examined. HLA-DRB1*17 was
transmitted (TR) 306 times and not transmitted (NT) 222
times; odds ratio (OR) ¼ 1.4, v
2 ¼ 13.36 (p ¼ 0.00026). HLA-
DRB1*14 continues to be protective; TR¼23, NT¼66, OR¼
0.35, v
2 ¼ 20.78 (p ¼ 5.23 10
 6) and HLA-DRB1*11 was also
found to be signiﬁcantly under transmitted (TR ¼ 157, NT ¼
213) even after applying a Bonferroni correction for multiple
testing (p¼0.0036, pc¼0.047). HLA-DRB1*08 (p¼0.0058) and
HLA-DRB1*12 (p ¼ 0.041) were over and under transmitted,
respectively, but would not be signiﬁcant after applying a
Bonferroni correction.
Transmission of HLA-DRB1 alleles to unaffected offspring
was also analysed. In the total sample, HLA-DRB1*15 was
transmitted 518 times and not transmitted 616 times; v
2 ¼
8.47 (p ¼ 0.0036, pc ¼ 0.047). Transmissions of HLA-DRB1*14
and HLA-DRB1*11 from non-HLA-DRB1*15-bearing parents
were TR ¼ 42, NT ¼ 42 (p ¼ 1) and TR ¼ 142, NT ¼ 161 (p ¼
0.28), respectively.
Mode of Inheritance of HLA-DRB1*15
The mode of inheritance of HLA-DRB1*15 was assessed by
examining the segregation of the allele in various mating
types (Table 1) where the genotypes of both parents were
available. The genotype HLA-DRB1*15/X had a 3.1-fold
increased risk of MS over HLA-DRB1*X/X (where ‘‘X’’ refers
to all alleles other than HLA-DRB1*15). An individual
homozygous for HLA-DRB1*15 had a 1.8-fold increased risk




Mode of Inheritance of HLA-DRB1*17
The mode of inheritance for the HLA-DRB1*17 suscepti-
bility allele was assessed in a similar manner. In the total
sample, HLA-DRB1*17/17 or HLA-DRB1*17/X showed no
increased frequency in the genotypes of the affected off-
spring (unpublished data). However, controlling for the
effects of HLA-DRB1*15 by assessing only those parents
lacking HLA-DRB1*15 (n ¼ 179 nuclear families), HLA-
DRB1*17 heterozygotes increased MS risk by 1.6-fold over
HLA-DRB1*X/X individuals (where ‘‘X’’ is neither HLA-
DRB1*15 nor DRB1*17) (Table 2). Additionally, HLA-
DRB1*17 homozygosity further increased risk by 2.2-fold
compared to a HLA-DRB1*17 heterozygote.
To test the relative and interactive effects of HLA-DRB1*17
and DRB1*15, the offspring genotypes of the mating type
HLA-DRB1*15/17 by HLA-DRB1*X/X (where ‘‘X’’ is neither
HLA-DRB1*15 nor DRB1*17) were examined. If the two
alleles are codominant in their mode of inheritance, there
should be an equal proportion of HLA DRB1*17/X and HLA-
DRB1*15/X offspring. In this mating type, there were 77 HLA-




 5). A conﬁrmation
of this can be given by the mating HLA-DRB1*15/X by HLA-
DRB1*17/X (where ‘‘X’’ is neither HLA-DRB1*15 nor
DRB1*17). If HLA-DRB1*15 were dominant to HLA-
DRB1*17, the numbers of HLA-DRB1*15/17 offspring and
HLA-DRB1*15/X offspring should be equal. In this mating
type, there were 74 HLA-DRB1*15/17 and 70 HLA-DRB1*15/X;
v
2 ¼ 0.11 (p ¼ 0.74).
Mode of Inheritance of HLA-DRB1*14
The inheritance of the resistance allele, HLA-DRB1*14 was
also examined. As with HLA-DRB1*17, the inheritance of
HLA-DRB1*14 was analysed with and without HLA-DRB1*15-
bearing parents. In the presence of HLA-DRB1*15 and
DRB1*17, the transmission of HLA-DRB1*14 was, expectedly,
signiﬁcantly under transmitted, OR¼0.31; v
2¼29.8, (p¼4.83
10
 8, pc ¼ 6.2 3 10
 7). When the over transmission of HLA-
DRB1*15 and DRB1*17 was controlled for, the OR of HLA-
DRB1*14 was still signiﬁcantly different from 1.0 (Table 3);
OR ¼ 0.27; (p ¼ 0.0096, pc ¼ 0.27). There were no HLA-
DRB1*14 homozygous parents, unaffected siblings, or MS
cases observed in the entire sample.
To further assess the relative effects of HLA DRB1*14 and
DRB1*15, the offspring genotypes from HLA-DRB1*15/X by
HLA-DRB1*14/X matings were examined (where ‘‘X’’ is
Table 1. The Inheritance of HLA-DRB1*15
Mating Offspring Genotype
15/15 versus 15/X 15/X versus X/X
15/X by X/X NA 557 by 183 (OR ¼ 3.0)
15/X by 15/X 107 by 56 (OR ¼ 1.9) 56 by 17 (OR ¼ 3.3)
15/15 by 15/X 53 by 33 (OR ¼ 1.6) NA
Total 160 by 89 (OR ¼ 1.8) 613 by 200 (OR ¼ 3.1)
v
2 value (p-value) 20.24 (p ¼ 6.8 3 10
 6;
pc ¼ 9.6 3 10
 5)
209.8 (p ¼ 1.5 3 10
 47;
pc ¼ 2.1 3 10
 46)
In all tables, NA means that no matings of this type are available or offspring genotypes
are not possible with parental genotypes.
doi:10.1371/journal.pgen.0030150.t001
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Author Summary
Multiple sclerosis (MS) is a complex neurological disease with a
strong genetic component. With the possible exception of a weak
association at Chromosome 5p, the major histocompatibility
complex is the only locus consistently linked to MS. Because of
this the major histocompatibility complex has recently undergone
renewed attention. A region at or near the gene HLA-DRB1
influences the risk of MS. HLA-DRB1 comes in over 400 different
forms (or alleles). A common form in Europe, named 1501, increases
risk of MS by 3-fold. In this paper, to our knowledge the largest-ever
analysis of this region in MS, we examine the inheritance of newly
discovered HLA-DRB1 MS resistance alleles, namely HLA-DRB1*14,
HLA-DRB1*11, *10, and HLA-DRB1*01. We show that HLA-DRB1*14
and HLA-DRB1*11 are dominantly protective; e.g., HLA-DRB1*14
significantly reduces the risk associated with HLA-DRB1*15 when
they are inherited together. This may explain, in part, why MS is rare
in Asia; there, the HLA-DRB1*14 allele is frequent. HLA-DRB1*01 and
HLA-DRB1*10 are protective only in the presence of HLA-DRB1*15.
HLA-DRB1*14 and HLA-DRB1*11 haplotypes and HLA-DRB1*01 and
HLA-DRB1*10 haplotypes share common ancestral origins and this
may be why the alleles can be grouped in terms of their protective
nature. Discovery of the mechanism of protection against MS may
lead to the discovery of new treatments to make a palpable
difference in the lives of those who have been affected by this
devastating disease.neither HLA-DRB1*15 nor DRB1*14). Possible offspring
genotypes are HLA-DRB1*15/14, DRB1*15/X, DRB1*14/X,
and DRB1*X/X.I fHLA-DRB1*15 acts dominantly, numbers
of HLA-DRB1*15/14 offspring should equal numbers of HLA-
DRB1*15/X offspring. Alternatively, if HLA-DRB1*14 acts
dominantly over HLA-DRB1*15, the numbers of HLA-
DRB1*15/14 offspring should be less than HLA-DRB1*15/X
offspring. A total of 24 HLA-DRB1*15/X offspring and seven
HLA-DRB1*15/14 offspring were observed (p ¼ 0.0017, pc ¼
0.048). The OR of HLA-DRB1*15/14 over HLA-DRB1*X/X (OR
¼ 0.5) was not signiﬁcantly different from expected, v
2 ¼ 1.6,
(p ¼ 0.21). However, when the frequency of HLA-DRB1*15/14
was compared between affected (n ¼ 10/2182) and unaffected
(n¼30/2126) siblings, the OR¼0.30, v
2¼10.63 (p¼0.0010, pc
¼0.028). Only one affected and one unaffected individual per
family were included and the individuals were chosen
randomly.
Mode of Inheritance of HLA-DRB1*11
HLA-DRB1*11 was demonstrated to be a resistance allele in
this cohort. To further evaluate the mode of inheritance of
this resistance allele we repeated the previous inheritance
analyses with HLA-DRB1*11 (Table 4). In HLA-DRB1*15-
negative families, there were 69 HLA-DRB1*11/X offspring
and 107 HLA-DRB1*X/X children (where ‘‘X’’ is neither HLA-
DRB1*15 nor DRB1*11); OR ¼ 0.64 (p ¼ 0.0042, pc ¼ 0.12).
HLA-DRB1*11/11 showed increased protection (OR ¼ 0.44);
however, this was not statistically signiﬁcant. When the
frequency of HLA-DRB1*11/11 was compared between
affected (n ¼ 4/2,182) and unaffected (n ¼ 13/2,126) siblings,
the OR ¼ 0.38, v
2 ¼ 5.02 (p ¼ 0.025, pc ¼ 0.7).
To examine the relative effects of HLA-DRB1*11 and
DRB1*15, matings of HLA-DRB1*11/X by HLA-DRB1*15/X
and HLA-DRB1*11/X and HLA-DRB1*15/15 (where ‘‘X’’ is
neither HLA-DRB1*15 nor DRB1*11) were assessed. There
were 57 HLA-DRB1*11/15 and 98 HLA-DRB1*15/X observed
genotypes in the offspring. The number of HLA-DRB1*11/15
children was signiﬁcantly decreased from the number of
HLA-DRB1*15/X offspring; OR¼0.58, v
2¼10.85 (p¼0.00099,
pc ¼ 0.028).
Mode of Inheritance of HLA-DRB1*08
To assess the inheritance pattern of HLA-DRB1*08, we
counted offspring in HLA-DRB1*08/X by HLA-DRB1*X/X
matings and HLA-DRB1*08/X by HLA-DRB1*08/X matings
(where ‘‘X’’ is not HLA-DRB1*08; there were no HLA-
DRB1*08/08 parents or affected children). There were 92
HLA-DRB1*08/X offspring and 83 HLA-DRB1*X/X offspring;
OR¼1.11 (p ¼0.50). When HLA-DRB1*15 was removed from
the sample in the above mating types, there were 36 HLA-
DRB1*08/X offspring and 21 HLA-DRB1*X/X children; OR ¼
1.7, v
2 ¼ 3.95 (p ¼ 0.047; pc ¼ 0.99).
To examine the relative effects of HLA-DRB1*08 and
DRB1*15, matings of HLA-DRB1*08/X by HLA-DRB1*15/X
and HLA-DRB1*08/X and HLA-DRB1*15/15 (where ‘‘X’’ is
neither HLA-DRB1*15 nor DRB1*08) were assessed. There
were 40 HLA-DRB1*08/15, ﬁve HLA-DRB1*08/X, 23 HLA-
DRB1*15/X, and nine HLA-DRB1*X/X observed genotypes in
the offspring. The number of HLA-DRB1*08/15 children was
signiﬁcantly increased from the number of HLA-DRB1*15/X
offspring; OR ¼ 1.74 (p ¼ 0.021; pc ¼ 0.44).
Mode of Inheritance of HLA-DRB1*10
HLA-DRB1*10 is a rare allele in this sample (allele
frequency ¼ 0.6%) and numbers and mating types were few.
However, in a previous investigation, it was found that HLA-
DRB1*10 may have acted to modulate risk [10]. In this new
dataset, the number of HLA-DRB1*15/10 to HLA-DRB1*15/X
offspring genotypes were compared in HLA-DRB1*10/X by
HLA-DRB1*15/X matings (where ‘‘X’’ is neither HLA-
DRB1*15 nor DRB1*10); the numbers were one and ten,
respectively, OR ¼ 0.09 (p ¼ 0.0059, pc ¼ 0.09).
In the absence of HLA-DRB1*15 (HLA-DRB1*10/X by HLA-
DRB1*X/X matings, where ‘‘X’’ is not HLA-DRB1*10 or
DRB1*15), an opposite trend was observed with 12 HLA-
DRB1*10/X offspring to seven HLA-DRB1*X/X offspring
found; OR ¼ 1.7 (p ¼ 0.18).
To further investigate this contrary ﬁnding, we repeated
the analysis of our previous investigation [10] using the newly
Table 3. The Inheritance of HLA-DRB1*14 in the Absence of HLA-
DRB1*15 and DRB1*17
Mating Offspring Genotype
14/14 versus 14/X 14/X versus X/X
14/X by X/X NA 3 by 12
14/X by 14/X 0 by 0 1 by 3
14/14 by 14/X 0 by 0 NA
Total 0 by 0 4 by 15 (OR ¼ 0.27)
v
2 value (p-value) — (p ¼ 0.0096; pc ¼ 0.27)
doi:10.1371/journal.pgen.0030150.t003
Table 4. The Mode of Inheritance of HLA-DRB1*11 in the
Absence of HLA-DRB1*15
Mating Offspring Genotype
11/11 versus 11/X 11/X versus X/X
11/X by X/X NA 58 by 100 (OR ¼ 0.58)
11/X by 11/X 2 by 4.5 (OR ¼ 0.44) 4.5 by 7 (OR ¼ 0.64)
11/11 by 11/X NA NA
Total 2 by 4.5 (OR ¼ 0.44) 62.5 by 107 (OR ¼ 0.58)
v
2 value (p-value) (p ¼ 0.34) 11.68 (p ¼ 0.00063; pc ¼ 0.018)
doi:10.1371/journal.pgen.0030150.t004
Table 2. The Inheritance of HLA-DRB1*17 in the Absence of HLA-
DRB1*15
Mating Offspring Genotype
17/17 versus 17/X 17/X versus X/X
17/X by X/X NA 94 by 60 (OR ¼ 1.6)
17/X by 17/X 14 by 7 (OR ¼ 2.0) 7 by 4 (OR ¼ 1.8)
17/17 by 17/X 9 by 3.5 (OR ¼ 2.6) NA
Total 23 by 10.5 (OR ¼ 2.2) 101 by 64 (OR ¼ 1.6)
v
2 value (p-value) (p ¼ 0.018; pc ¼ 0.50) 8.30 (p ¼ 0.0040; pc ¼ 0.11)
doi:10.1371/journal.pgen.0030150.t002
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5).
In the new sample, the trend was in the same direction as
the original ﬁnding in the Dyment et al. investigation [10].
When the results were combined, there was a signiﬁcant
difference in transmission of HLA-DRB1*10 from non-HLA-
DRB1*15 parents based on the presence or absence of HLA-
DRB1*15 in the offspring.
Mode of Inheritance of HLA-DRB1*01
In our previous investigation [10], we saw differences in the
transmission of HLA-DRB1*01 based on the presence or
absence of HLA-DRB1*15.W h i l eHLA-DRB1*01 is not
protective in the total transmission disequilibrium test
(TDT) from non-HLA-DRB1*15-bearing parents (TR ¼ 185,
NT¼195, p ¼0.61), further evaluation is warranted based on
previous observations.
To examine the relative effects of HLA-DRB1*01 and
DRB1*15, matings of HLA-DRB1*01/X by HLA-DRB1*15/X
and HLA-DRB1*01/X and HLA-DRB1*15/15 (where ‘‘X’’ is
neither HLA-DRB1*15 nor DRB1*01) were assessed. There
were 50 HLA-DRB1*01/15 and 85 HLA-DRB1*15/X observed
genotypes in the offspring. The number of HLA-DRB1*01/15
children was signiﬁcantly decreased from the number of
HLA-DRB1*15/X offspring; OR¼0.59, v
2¼9.1 (p¼0.0026, pc¼
0.036).
Case and Pseudo-Control Analysis
HLA-DRB1 alleles affecting MS risk were assessed by
stepwise model selection, starting with a full model contain-
ing effects of each allele observed in the sample with
frequency of at least ten across cases and pseudo-controls.
Four alleles, HLA-DRB1*15, HLA-DRB1*14, HLA-DRB1*17,
and HLA-DRB1*11, are signiﬁcantly associated with disease.
The same model was obtained using forward selection from
the null model. The overall ﬁt of the model was assessed by
means of the Wald v
2 statistic of 258.58 on four degrees of
freedom, providing strong evidence of association of HLA-
DRB1 alleles with MS (p ¼ 9.2 3 10
 55).
Model selection techniques tend to over ﬁt the data, and
result in increased false positive error rates for detecting
association with disease. To overcome this problem, we
performed 1,000 random permutations of case and pseudo-
control status within each matched set. In none of the
permutations did the selected model ﬁt as well as in the
original data, corresponding to an empirical p-value of less
than 0.001 for association of HLA-DRB1 alleles with MS.
Table 6 presents the ORs of MS for each associated allele,
relative to all non-associated alleles, denoted HLA-DRB1*X
forthwith. The strongest effect is observed for allele HLA-
DRB1*15, which increases risk of MS (OR ¼ 2.46, p ¼ 1.2 3
10
 47). Allele HLA-DRB1*17 also increases risk of MS (OR ¼
1.28, p¼0.0021). Alleles HLA-DRB1*14 and HLA-DRB1*11 are
protective against MS (ORs ¼ 0.41 and 0.77, respectively; p ¼
4.9 3 10
 5 and p ¼ 0.0080, respectively).
We next investigated deviations from a multiplicative
model of disease risk between associated alleles. We gener-
ated a full model including a non-multiplicative effect for
each associated allele, and interactions between each pair of
associated alleles. Application of stepwise model selection,
starting with the full model, dropped all interaction terms
and non-multiplicative terms, apart from a dominance effect
of the HLA-DRB1*15 allele (OR 0.68, p ¼ 0.0078). Associated
alleles act in a multiplicative fashion with respect to risk of
MS, except for allele HLA-DRB1*15, which acts in an additive
fashion with itself.
Table 7 presents ORs of MS for each HLA-DRB1 genotype,
relative to HLA-DRB1*X homozygotes. As described above,
the risk of associated alleles acts in a multiplicative fashion so
that, e.g., an individual carrying one copy of the high-risk
HLA-DRB1*15 allele and one copy of the strongly protective
HLA-DRB1*14 allele has the same risk of MS as a HLA-
DRB1*X/X individual (OR¼1.06, p¼0.85). In other words, the
effect of the HLA-DRB1*15 allele is cancelled out by the HLA-
DRB1*14 allele. The HLA-DRB1*11 allele also provides some
protection against the HLA-DRB1*15 allele, since the risk of
the HLA-DRB1*11/15 genotype is lower than that of the HLA-
DRB1*15/X genotype (OR¼2.44 and 2.92, respectively). HLA-
DRB1*11 provides protection against the high-risk HLA-
DRB1*17 allele (OR of the HLA-DRB1*11/17 genotype¼0.98,
p¼0.93). The HLA-DRB1*15 allele acts in a nonmultiplicative
fashion with itself. Individuals homozygous for the HLA-
DRB1*15 allele are at less risk of MS compared to the HLA-
DRB1*15/X genotype than would be expected under a
multiplicative disease model (OR ¼ 5.43 and 2.92, respec-
tively).
Interaction of the HLA-DRB1*15 Allele with Non-associated
Alleles
Previous studies have shown that non-associated alleles at
the HLA-DRB1 locus interact with the HLA-DRB1*15 allele to
modulate disease risk [10]. We investigated this by including
interaction effects of each non-associated allele with HLA-
DRB1*15 in a full association model. Stepwise model
selection dropped all interaction terms, with the exception
of the effects of the HLA-DRB1*07/15, HLA-DRB1*08/15, and
Table 5. Transmission of HLA-DRB1*10 from non-HLA-DRB1*15-







TR NT TR NT
Dyment et al. [10] 1 6 9 4 0.019
New samples 0 4 5 4 0.057
Combined 1 10 14 8 0.0030
doi:10.1371/journal.pgen.0030150.t005
Table 6. Allelic ORs of MS for Associated Alleles at the HLA-DRB1
Locus, Relative to All Non-associated Alleles
Allele OR 95% Confidence Interval p-Value
HLA-DRB1*15 2.461 2.179–2.780 1.2 3 10
 47
HLA-DRB1*14 0.414 0.271–0.634 4.9 3 10
 5
HLA-DRB1*17 1.278 1.093–1.493 0.0021
HLA-DRB1*11 0.768 0.632–0.934 0.0080
doi:10.1371/journal.pgen.0030150.t006
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DRB1*08/15 genotypes demonstrate increased risk of MS
compared to the HLA-DRB1*X/15 genotype (OR ¼ 1.28 and
1.65, respectively; p ¼ 0.038 and p ¼ 0.016, respectively). On
the other hand, the HLA-DRB1*10/15 appears protective
compared to the HLA-DRB1*X/15 genotype (OR ¼ 0.12, p ¼
0.044).
Discussion
The only consistent genetic association with MS in North-
ern Europeans has been with extended MHC haplotypes,
especially those containing HLA-DRB1*1501 [8]. A previously
linked region on Chromosome 5p13 [14] has been shown to
harbor the interleukin 7 receptor gene (IL7R), an additional
MS susceptibility locus [15], but any effect of IL7R is small
(OR¼1.3), and when compared to the MHC (genotypic OR¼
5.4, p ¼ 5 3 10
 33), its effect size is clearly too small to
inﬂuence inheritance patterns. The MS MHC association has
been used to add to circumstantial evidence supporting an
autoimmune reaction against myelin-related antigens pre-
sented to T cells in the restricting context of HLA-
DRB1*1501. However, the speciﬁc susceptibility gene (e.g.,
HLA-DR or HLA-DQ) or the speciﬁc mechanism of class II
determined susceptibility has yet to be convincingly eluci-
dated. Recent scans of the MHC region with a large number
of markers do show evidence for the involvement of HLA-
DRB1 only [16]. However, the paradigm is more complex than
one in which the HLA-DRB1*15 allele acts solely to increase
MS risk [10,13]. Our previous investigation showed the
presence of HLA-DRB1*14 as a resistance allele, HLA-
DRB1*17 as a susceptibility allele, and the more compelling
observation that alleles are interacting and that it is the
genotype that determines MS risk [10]. This expanded
Canadian dataset extends these results. We conﬁrm that
HLA-DRB1*15- and HLA-DRB1*17-bearing haplotypes in-
crease risk of MS, and HLA-DRB1*14-bearing haplotypes are
protective, and show that HLA-DRB1*11-bearing haplotypes
are novel and statistically signiﬁcant resistance haplotypes
(Table 6). To our knowledge, this study provides the most
comprehensive analysis to date of HLA susceptibility and
resistance alleles for multiple sclerosis.
The protective effect of the HLA-DRB1*14 haplotype is
shown to be multiplicative and completely abrogates the risk
associated with HLA-DRB1*15 (Table 7). HLA-DRB1*14
homozygotes were not observed in our sample (either
affected or unaffected relatives) in order to assess a possible
increased protection conferred by HLA-DRB1*14 homozygos-
ity, analogous to the increased susceptibility conferred by
HLA-DRB1*15 and DRB1*17 homozygosity. In populations
with a high frequency of HLA-DRB1*14, e.g., China [17],
where the existence of HLA-DRB1*14 homozygotes may be
substantial, the prevalence of MS is extremely low. Thus,
HLA-DRB1*14 could inﬂuence the distribution of MS and
suggests more broadly that the HLA-DRB1 genotype, which
reﬂects more complex interactions, may be a major determi-
nant of the heretofore unexplained geography of this disease.
HLA-DRB1*11 haplotypes also show a multiplicative mode
of inheritance (Table 7). The protective effect of HLA-
DRB1*11 over HLA-DRB1*15 appears to be weaker than that
of HLA-DRB1*14, but both reduce the risk associated with
HLA-DRB1*17.
We now show that HLA-DRB1*10-bearing haplotypes are
similar to HLA-DRB1*01-bearing haplotypes in that they are
both signiﬁcantly under transmitted in the presence of HLA-
DRB1*15, showing a clear protective effect in the presence of
HLA-DRB1*15 (Table 5). HLA-DRB1*10 and HLA-DRB1*01
were not under transmitted in the presence of HLA-DRB1*17
(unpublished data).
HLA-DRB1*15 heterozygotes have an increased risk of MS
with an OR of 2.9 (Tables 1 and 7). The HLA-DRB1*15/15
offspring genotype also increases risk over HLA-DRB1*X/X by
5.4-fold, and is in keeping with an additive mode of
inheritance for HLA-DRB1*15, similar to other studies
[12,18–21].
When the relative effects of HLA-DRB1*15 versus HLA-
DRB1*17 were compared, HLA-DRB1*15 was found to be
preferentially transmitted, most notably when transmissions
from HLA-DRB1*17/15 heterozygous parents were counted,
thereby ruling out a codominant model for these two risk
alleles. This is also in keeping with previous observations [10].
Table 7. Genotypic ORs of MS Made Up of Associated Alleles at the HLA-DRB1 Locus, Relative to HLA-DRB1*X Homozygotes
Genotype Number of Cases Number of Pseudo-Controls OR 95% Confidence Interval p-Value
X/X 351 1490 Baseline — —
X/11 83 437 0.742 0.561–0.983 0.038
X/14 12 105 0.418 0.199–0.878 0.021
X/15 584 1291 2.919 2.424–3.514 1.2 3 10
 29
X/17 183 657 1.343 1.057–1.705 0.016
11/11 4 29 0.457 0.184–1.133 0.091
11/14 4 16 0.731 0.234–2.286 0.59
11/15 78 183 2.440 1.762–3.379 7.9 3 10
 8
11/17 27 124 0.976 0.586–1.625 0.93
14/14 0 5 — — —
14/15 10 48 1.064 0.558–2.028 0.85
14/17 3 22 0.588 0.169–2.045 0.40
15/15 160 248 5.428 4.116–7.159 4.5 3 10
 33
15/17 151 311 3.269 2.503–4.270 3.3 3 10
 18
17/17 34 86 2.109 1.287–3.454 0.0031
doi:10.1371/journal.pgen.0030150.t007
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recessive manner [12,13,21], but the sample size has been
smaller than the one in the present study. In this Canadian
sample, HLA-DRB1*17 haplotypes act in an additive fashion
(Tables 2 and 7).
HLA-DRB1*08 increases risk signiﬁcantly with HLA-
DRB1*15 in trans. Thus, HLA-DRB1*08 shows a synergistic
mode of inheritance with HLA-DRB1*15. HLA-DRB1*17
shows no interaction with HLA-DRB1*08 (unpublished data),
further highlighting the difference between HLA-DRB1*15
and HLA-DRB1*17 haplotypes.
As yet, no molecular or functional explanation can be
given for the dominant-negative effects of HLA-DRB1*14
and DRB1*11, the complementary effects of HLA-DRB1*08,
and the protective nature of HLA-DRB1*01 and DRB1*10 in
the presence of HLA-DRB1*15. It has been speculated that
poor engagement of the encephalitogenic peptide in the
context of HLA-DRB1*14 acts to alter the immune response
in a dominant-negative manner and thereby reduce the
effect of HLA-DRB1*15 [13]. Another explanation is that
HLA-DRB1*14 binds one or more peptides that can delete
autoreactive T cells. Alternatively, other risk factors present
on HLA-DRB1 haplotypes could be interacting in cis and trans
to reduce MS risk. HLA-DRB1 allelic association with MS
susceptibility and resistance may reﬂect linkage disequili-
brium with the true disease locus/loci. The identity and
location of these putative variants are unknown and will be
difﬁcult to identify given the high linkage disequilibrium
present within the MHC, although it is likely that these
variants, if they exist, will be found in the class II region
[16,22]. Susceptibility and resistance haplotypes may need
revisiting if/when true or additional MS MHC susceptibility
loci are uncovered. As mentioned previously [10], HLA-
DRB1*14, DRB1*10, and DRB1*01 share the extended HLA-
DQ haplotype HLA-DQA1*01-DQB1*05, which may protect
against MS. However,H L A - D R B 1 * 1 1haplotypes do not share
these HLA-DQ alleles. Interestingly, phylogenetic analysis
suggests that HLA-DRB1*10 and DRB1*01 share the same
allelic lineage (DR1 group) and HLA-DRB1*11, DRB1*14, and
DRB1*12 belong to the DR52 group [23]. Variants on the
similar HLA-DRB1*10 and DRB1*01 haplotypes could enable
them to be protective in the presence of HLA-DRB1*15.
HLA-DRB1*14 and DRB1*11 haplotypes may also possess
similar polymorphisms that give them a dominant-protective
effect.
It has been shown that low immune responsiveness to
certain antigens are HLA-linked dominant traits [24]; this was
proposed to be caused by an immune suppression gene
present on certain HLA haplotypes that controls the
generation of antigen-speciﬁc suppressor T cells [25].
Recently, HLA-DRB5*0101 has been shown to reduce the
number of autoreactive CD4
þ T cells in experimental auto-
immune encephalomyelitis models [26]. It is conceivable that
dominant variants on HLA-DRB1*14 and HLA-DRB1*11
haplotypes can generate T cells that suppress autoreactive T
cells, even those generated by HLA-DRB1*15.
This study highlights the need for a large sample size and
systematic methods of analysis (e.g., stratiﬁed TDT is a more
sensitive measure to detect interactions between alleles than
regression) in order to unravel the complexity of HLA
associations. Further studies of HLA expression, and/or
animal models incorporating the susceptibility and resistance
genotypes, are warranted to explain these complex inter-
actions. In the meantime, genotyping for susceptibility and
resistance alleles may have some practical value in prospec-
tive studies of prevention.
Materials and Methods
Participants. All participants in the study were ascertained through
the ongoing CCPGSMS, for which the methodology has been
previously described [27].
Genotyping. Total genomic DNA, extracted from whole blood as
part of the CCPGSMS, was used to type HLA-DRB1 alleles by an
allele-speciﬁc PCR ampliﬁcation method [28]. All genotypes were
generated blind to pedigree structure and disease status of the
individual. Either 24 (low resolution) or 72 (high resolution) PCRs
were carried out to amplify allelotypes corresponding to alleles HLA-
DRB1*01, HLA-DRB1*04, HLA-DRB1*07, HLA-DRB1*08, HLA-
DRB1*09, HLA-DRB1*10, HLA-DRB1*11, HLA-DRB1*12, HLA-
DRB1*13, HLA-DRB1*14, HLA-DRB1*15, HLA-DRB1*16, HLA-
DRB1*17, and HLA-DRB1*18, as well as products for the DRB3,
DRB4, and DRB5 genes. Each HLA-DRB1 genotype was scored twice
by independent observers.
Statistical analyses. TDT was performed using the sib_tdt
program of the ASPEX 2.3 analysis package (available at http://
aspex.sourceforge.net/). The TDT counts the number of times an
allele is transmitted to affected offspring from heterozygous parents.
For TDTs the v
2 distribution was used to assess signiﬁcance, except in
TDTs where the sum of transmissions and non-transmissions was less
than 50, when the exact binomial test was used. For allele inheritance
analysis, a highly conservative Bonferroni correction was applied to
correct for the number of statistical tests made for each allele, and for
the total number of alleles investigated (n¼7). Corrected p-values are
shown as pc.
Association of HLA-DRB1 alleles with MS was assessed by condi-
tional logistic regression with each MS case matched to pseudo-
controls, formed from the possible offspring that could have
occurred from the parental mating [29]. The genotype of each
individual was coded in terms of an indicator variable (0, 1, or 2) for
each allele. Association of HLA-DRB1 alleles was then assessed by
stepwise model selection, with allelic effects added or removed at
each stage if p , 0.05. Dominance effects of each allele were coded by
additional indicator variables, taking the value 1 if an individual is
homozygous for the allele and 0 otherwise. Interaction effects
between alleles were generated by introducing further indicator
variables that are products of the corresponding allelic effects. To
allow for correlations between multiple affected offspring from the
same family, cases and matched pseudo-controls were clustered by
pedigree and robust Huber-White estimators used to adjust the
standard errors of ORs [30].
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